1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
about
Mitigating epidemic vitamin D deficiency: the agony of evidenceEtiology, diagnosis, and therapeutic management of granuloma annulare: an update.Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.Inverse psoriasis involving genital skin folds: successful therapy with dapsoneIs pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review.Proctology - diseases of the anal region.Skin disease of penis and male genitalia is linked to atopy and circumcision: caseload in a male genital dermatology clinic.Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis.Topical Therapies in Psoriasis.Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial.Topical treatment habits in psoriasis patients receiving adalimumab.Atténuer la carence épidémique en vitamine D: La tourmente des données scientifiques.
P2860
Q34506209-D7CB83FF-EE3A-49B6-AA11-47C5296F507DQ34733315-7CA80D8C-8077-4A67-9BD6-028AD1B61F6EQ34740267-93503FDE-14D4-49CA-A635-D06F3477005BQ36434768-517FDAF9-E5AF-4CE0-81B1-7F4A76F08D26Q36577730-4400E125-58CE-4243-938B-990358793016Q38003486-A455DE8A-0685-422A-9A74-BAF87155CAB7Q38793499-BCD00CA0-4F39-4CC3-B203-A0FADD4091E6Q38832496-F2A10114-4282-491D-A871-516B43AF67C1Q38841466-40D695FA-47C3-4CB2-AD03-FCF1C13BE5CEQ41068232-BF7307A8-12B5-449C-AACE-CD7AEEEE9933Q46951901-EDA858F1-7A94-41B7-85D1-41B338A1686FQ51353479-F6EEAB70-DC5E-450F-9602-6A8400162927Q55464142-12ACB6EF-2E1B-42A8-AB01-A36F3887D545
P2860
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@ast
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@en
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@nl
type
label
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@ast
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@en
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@nl
prefLabel
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@ast
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@en
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@nl
P2093
P1433
P1476
1% pimecrolimus, 0.005% calcip ...... , randomized controlled study.
@en
P2093
Alexander Kreuter
Anna Sommer
Julia Hyun
Matthias Bräutigam
Norbert H Brockmeyer
Peter Altmeyer
Thilo Gambichler
P304
P356
10.1001/ARCHDERM.142.9.1138
P577
2006-09-01T00:00:00Z